<!DOCTYPE html>
<html class="writer-html5" lang="en" >
<head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
      <link rel="shortcut icon" href="../../img/favicon.ico" />
    <title>Bibliography - RGDS Independent Study — Decision-Centric AI Governance</title>
    <link rel="stylesheet" href="../../css/theme.css" />
    <link rel="stylesheet" href="../../css/theme_extra.css" />
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/styles/github.min.css" />
    
      <script>
        // Current page data
        var mkdocs_page_name = "Bibliography";
        var mkdocs_page_input_path = "references/bibliography.md";
        var mkdocs_page_url = null;
      </script>
    
    <!--[if lt IE 9]>
      <script src="../../js/html5shiv.min.js"></script>
    <![endif]-->
      <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/highlight.min.js"></script>
      <script>hljs.highlightAll();</script> 
</head>

<body class="wy-body-for-nav" role="document">

  <div class="wy-grid-for-nav">
    <nav data-toggle="wy-nav-shift" class="wy-nav-side stickynav">
    <div class="wy-side-scroll">
      <div class="wy-side-nav-search">
          <a href="../.." class="icon icon-home"> RGDS Independent Study — Decision-Centric AI Governance
        </a><div role="search">
  <form id ="rtd-search-form" class="wy-form" action="../../search.html" method="get">
      <input type="text" name="q" placeholder="Search docs" aria-label="Search docs" title="Type search term here" />
  </form>
</div>
      </div>

      <div class="wy-menu wy-menu-vertical" data-spy="affix" role="navigation" aria-label="Navigation menu">
              <ul>
                <li class="toctree-l1"><a class="reference internal" href="../..">Home</a>
                </li>
              </ul>
              <p class="caption"><span class="caption-text">Research Questions</span></p>
              <ul>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q1/">1. Decision Reconstructability</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q2/">2. AI Accountability</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q3/">3. Integration Without Overhead</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q4/">4. Schema Validation & Risk Reduction</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q5/">5. Decision Velocity</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q6/">6. Strategic Reshaping</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q7/">7. ROI Measurement</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q8/">8. Implementation Roadmaps</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q9/">9. AI Governance Disclosure</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/q10/">10. Regulatory Evolution</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../../questions/results-overview/">Results Overview</a>
                  </li>
              </ul>
              <p class="caption"><span class="caption-text">References</span></p>
              <ul class="current">
                  <li class="toctree-l1"><a class="reference internal" href="../about-the-author/">About the Author</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../acknowledgements/">Acknowledgements</a>
                  </li>
                  <li class="toctree-l1 current"><a class="reference internal current" href="#">Bibliography</a>
    <ul class="current">
    <li class="toctree-l2"><a class="reference internal" href="#tier-1-directly-cited-sources-67-sources-70">Tier 1: Directly Cited Sources (~67 sources, 70%)</a>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#tier-2-consulted-sources-29-sources-30">Tier 2: Consulted Sources (~29 sources, 30%)</a>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#why-this-approach">Why This Approach</a>
    </li>
    </ul>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../appendix-a/">Appendix A</a>
                  </li>
              </ul>
      </div>
    </div>
    </nav>

    <section data-toggle="wy-nav-shift" class="wy-nav-content-wrap">
      <nav class="wy-nav-top" role="navigation" aria-label="Mobile navigation menu">
          <i data-toggle="wy-nav-top" class="fa fa-bars"></i>
          <a href="../..">RGDS Independent Study — Decision-Centric AI Governance</a>
        
      </nav>
      <div class="wy-nav-content">
        <div class="rst-content"><div role="navigation" aria-label="breadcrumbs navigation">
  <ul class="wy-breadcrumbs">
    <li><a href="../.." class="icon icon-home" aria-label="Docs"></a></li>
          <li class="breadcrumb-item">References</li>
      <li class="breadcrumb-item active">Bibliography</li>
    <li class="wy-breadcrumbs-aside">
    </li>
  </ul>
  <hr/>
</div>
          <div role="main" class="document" itemscope="itemscope" itemtype="http://schema.org/Article">
            <div class="section" itemprop="articleBody">
              
                <h1 id="bibliography">Bibliography<a class="headerlink" href="#bibliography" title="Permanent link">&para;</a></h1>
<p><strong>Note on Sources:</strong> This bibliography comprises 96 sources organized across two tiers:</p>
<h3 id="tier-1-directly-cited-sources-67-sources-70">Tier 1: Directly Cited Sources (~67 sources, 70%)<a class="headerlink" href="#tier-1-directly-cited-sources-67-sources-70" title="Permanent link">&para;</a></h3>
<p>These sources are cited inline throughout Questions 1-10 in support of specific evidentiary claims:</p>
<ul>
<li>FDA regulatory data (Complete Response Letter trends, clinical hold rates, deficiency patterns)</li>
<li>Decision governance case studies and research (Syner-G operational data, governance modernization trends)</li>
<li>AI governance and regulatory guidance (FDA January 2025 AI guidance, credibility frameworks)</li>
<li>Investor valuation research (governance premiums, due diligence frameworks)</li>
<li>Financial impact analysis (Form 483 costs, delay costs, ROI calculations)</li>
<li>Project management research (RACI frameworks, role clarity benefits, project success factors)</li>
</ul>
<p>All evidentiary claims are fully traceable through inline citations.</p>
<h3 id="tier-2-consulted-sources-29-sources-30">Tier 2: Consulted Sources (~29 sources, 30%)<a class="headerlink" href="#tier-2-consulted-sources-29-sources-30" title="Permanent link">&para;</a></h3>
<p>These sources were reviewed to inform analytical method, regulatory context, and synthesis but are not cited inline. They include:</p>
<ul>
<li>Global AI regulation frameworks (comparative analysis across jurisdictions)</li>
<li>Governance modernization theory (organizational adoption patterns, change management models)</li>
<li>Implementation science frameworks (scale, adoption, organizational readiness)</li>
<li>FDA policy evolution and IT infrastructure modernization plans</li>
<li>Portfolio management and valuation methodologies</li>
<li>Change management best practices (pharma-specific adoption studies)</li>
</ul>
<p>Consulted sources shaped the regulatory landscape context and implementation methodology presented in Q8 and informed the broader interpretive framework for governance modernization, but they were not required for supporting specific claims.</p>
<h3 id="why-this-approach">Why This Approach<a class="headerlink" href="#why-this-approach" title="Permanent link">&para;</a></h3>
<p>This two-tiered citation approach is standard in applied research and policy analysis. It distinguishes between evidence attribution (inline citations) and analytical foundation (consulted sources). Readers seeking to verify the contribution of any consulted source may reference the bibliographic entry.</p>
<hr />
<p><a id="cite1"></a> [1] Learning from the Letters: FDA Complete Response Letter Trends (2020–2024) and What They Mean for Sponsors</p>
<ul>
<li>Published:July 14, 2025</li>
<li>URL: <a href="https://www.auriacompliance.com/gmp-blog/learning-from-the-letters-fda-complete-response-letter-trends-20202024-and-what-they-mean-for-sponsors">https://www.auriacompliance.com/gmp-blog/learning-from-the-letters-fda-complete-response-letter-trends-20202024-and-what-they-mean-for-sponsors</a></li>
<li>Access: Auriacompliance regulatory insights blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite2"></a> [2] Investigational New Drug Applications: A 1‑Year Pilot Study on Rates and Reasons for Clinical Hold</p>
<ul>
<li>Published: 2016 (Journal of Investigative Medicine)</li>
<li>URL: <a href="https://pubmed.ncbi.nlm.nih.gov/26911627">https://pubmed.ncbi.nlm.nih.gov/26911627</a></li>
</ul>
<p><a id="cite3"></a> [3] What is a Complete Response Letter?</p>
<ul>
<li>Publisher: Avalere Health</li>
<li>Date: November 30, 2023</li>
<li>URL: <a href="https://avalere.com/insights/what-is-a-complete-response-letter">https://avalere.com/insights/what-is-a-complete-response-letter</a></li>
<li>Notes: Explains CRLs and notes CRL frequency in the 2018–2022 PDUFA cycle.</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite4"></a> [4] Multiplier AI Medical Writing Platform – Case Study of AI‑Assisted Regulatory Authoring</p>
<ul>
<li>Published:2025</li>
<li>URL: <a href="https://multiplierai.co/medical-writing/">https://multiplierai.co/medical-writing/</a></li>
<li>Access: Multiplier AI product case‑study page</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite5"></a> [5] Axtria Rapid CSR: AI‑Automated Clinical Study Report Authoring</p>
<ul>
<li>Published: March 3, 2025</li>
<li>URL: <a href="https://analyticsindiamag.com/ai-highlights/revolutionise-your-research-with-axtria-rapid-csr-for-faster-more-accurate-clinical-study-reports/">https://analyticsindiamag.com/ai-highlights/revolutionise-your-research-with-axtria-rapid-csr-for-faster-more-accurate-clinical-study-reports/</a></li>
<li>Access: Analytics India Magazine news article</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite6"></a> [6] Life Science GenAI Software for Medical Writing | CoAuthor™</p>
<ul>
<li>Publisher: Certara</li>
<li>Date: Accessed January 5, 2026</li>
<li>URL: <a href="https://www.certara.com/coauthor/">https://www.certara.com/coauthor/</a></li>
<li>Notes: Certara product page describing CoAuthor features and claimed efficiency gains.</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite7"></a> [7] Dr.Evidence: AI Labeling &amp; Regulatory Intelligence Platform</p>
<ul>
<li>Publisher: Dr.Evidence</li>
<li>Date: Accessed January 5, 2026</li>
<li>URL: <a href="https://www.drevidence.com/">https://www.drevidence.com/</a></li>
<li>Notes: Product page describing access to large regulatory/labeling document corpora and landscape intelligence.</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite8"></a> [8] How AI is transforming global regulatory processes</p>
<ul>
<li>Publisher: IQVIA</li>
<li>Date: September 24, 2025</li>
<li>URL: <a href="https://www.iqvia.com/blogs/2025/09/how-ai-is-transforming-global-regulatory-processes">https://www.iqvia.com/blogs/2025/09/how-ai-is-transforming-global-regulatory-processes</a></li>
<li>Notes: Overview of AI use in regulatory intelligence, comparisons, and pattern detection across markets.</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite9"></a> [9] Transformative roles of digital twins from drug discovery to continuous manufacturing: biopharma/biotech and biopharmaceutical perspectives</p>
<ul>
<li>Publisher: International Journal of Pharmaceutics: X (Elsevier)</li>
<li>Date: 2025</li>
<li>URL: <a href="https://www.sciencedirect.com/science/article/pii/S2590156725000945">https://www.sciencedirect.com/science/article/pii/S2590156725000945</a></li>
<li>Notes: Open-access review of digital twin applications in pharma/biopharma, including manufacturing optimization and predictive analytics.</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite10"></a> [10] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products</p>
<ul>
<li>Publisher: U.S. Food and Drug Administration (FDA)</li>
<li>Date: January 6, 2025</li>
<li>URL: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological</a></li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite11"></a> [11] Governance Premiums and Investor Valuation Adjustments</p>
<ul>
<li>Published: March 2006</li>
<li>URL: <a href="https://www.ifc.org/content/dam/ifc/doc/mgrt/irresistiblecase4cg.pdf">https://www.ifc.org/content/dam/ifc/doc/mgrt/irresistiblecase4cg.pdf</a></li>
<li>Access: International Finance Corporation (IFC) corporate governance report</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite12"></a> [12] AI | NEXT Medical Writing Automation</p>
<ul>
<li>Publisher: Trilogy Writing &amp; Consulting (Indegene)</li>
<li>Date: Accessed January 5, 2026</li>
<li>URL: <a href="https://trilogywriting.com/ai/">https://trilogywriting.com/ai/</a></li>
<li>Notes: Platform overview for AI-supported medical writing automation and transparency/traceability framing.</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite13"></a> [13] Modernizing Pharma Governance for Faster Portfolio Decisions</p>
<ul>
<li>Published: 2025</li>
<li>URL: <a href="https://www.worldpharmatoday.com/techno-trends/modernizing-governance-structures-for-faster-portfolio-decisions/">https://www.worldpharmatoday.com/techno-trends/modernizing-governance-structures-for-faster-portfolio-decisions/</a></li>
<li>Access: World Pharma Today technology trends article</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite14"></a> [14] Project Management for the Biopharma/biotech Industry (Guidance Document)</p>
<ul>
<li>Publisher: ISPE (International Society for Biopharma/biotech Engineering)</li>
<li>Date: Accessed January 5, 2026</li>
<li>URL: <a href="https://ispe.org/publications/guidance-documents/project-management-biopharma/biotech-industry">https://ispe.org/publications/guidance-documents/project-management-biopharma/biotech-industry</a></li>
<li>Notes: Industry guidance on pharma project management tools/techniques and integrating compliance into project delivery.</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite15"></a> [15] Quality Control Process for Regulatory Submissions: Cross‑Functional Teams and Tiered Reviews</p>
<ul>
<li>Published: 2025</li>
<li>URL: <a href="https://www.pharmaregulator.in/quality-control-process-regulatory-submissions">https://www.pharmaregulator.in/quality-control-process-regulatory-submissions</a></li>
<li>Access: PharmaRegulatory white paper</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite16"></a> [16] RACI Matrix: Clarifying Roles and Eliminating Ambiguity</p>
<ul>
<li>Published: April 2025</li>
<li>URL: <a href="https://plprojects.co.uk/raci-matrix-project-management/">https://plprojects.co.uk/raci-matrix-project-management/</a></li>
<li>Access: PL Projects project‑management article</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite17"></a> [17] Clear Roles Increase Project Success: Insights from the Project Management Institute</p>
<ul>
<li>Published: 2024</li>
<li>URL: <a href="https://plprojects.co.uk/raci-benefits-and-pmi-research">https://plprojects.co.uk/raci-benefits-and-pmi-research</a></li>
<li>Access: PL Projects article citing Project Management Institute research</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite18"></a> [18] Critical Path Method: Managing Project Duration and Constraints</p>
<ul>
<li>Published: 2025</li>
<li>URL: <a href="https://www.teamgantt.com/critical-path-method-guide">https://www.teamgantt.com/critical-path-method-guide</a></li>
<li>Access: TeamGantt project‑management guide</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite19"></a> [19] Cross‑Functional Review: Peer, QC, and Functional Lead Approvals</p>
<ul>
<li>Published: 2025</li>
<li>URL: <a href="https://www.pharmaregulator.in/quality-control-process-regulatory-submissions">https://www.pharmaregulator.in/quality-control-process-regulatory-submissions</a></li>
<li>Access: PharmaRegulatory white paper</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite20"></a> [20] Standardized Documentation and Error Reduction through Tiered QA</p>
<ul>
<li>Published: 2024</li>
<li>URL: <a href="https://docsie.io/blog/quality-control-documentation-best-practices">https://docsie.io/blog/quality-control-documentation-best-practices</a></li>
<li>Access: Docsie documentation best‑practices article</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite21"></a> [21] Target Product Profile: Strategic Blueprint Aligning Development and Labeling</p>
<ul>
<li>Published: 2024</li>
<li>URL: <a href="https://intuitionlabs.ai/articles/target-product-profile-strategy">https://intuitionlabs.ai/articles/target-product-profile-strategy</a></li>
<li>Access: Intuition Labs article</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite22"></a> [22] Biopharma/biotech Portfolio Management: A Complete Primer (Risk Appetite, Prioritization, and Governance)</p>
<ul>
<li>Published: May 21, 2023</li>
<li>URL: <a href="https://www.planview.com/resources/articles/biopharma/biotech-portfolio-management-a-complete-primer/">https://www.planview.com/resources/articles/biopharma/biotech-portfolio-management-a-complete-primer/</a></li>
<li>Access: Planview resources</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite23"></a> [23] A Strategic Investor's Guide to Biopharma/biotech Portfolio Risk Assessment</p>
<ul>
<li>Published: December 10, 2025</li>
<li>URL: <a href="https://www.drugpatentwatch.com/blog/a-strategic-investors-guide-to-biopharma/biotech-portfolio-risk-assessment/">https://www.drugpatentwatch.com/blog/a-strategic-investors-guide-to-biopharma/biotech-portfolio-risk-assessment/</a></li>
<li>Access: DrugPatentWatch industry analysis</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite24"></a> [24] Clinical Holds for Cell and Gene Therapy Trials: Duration and Causes</p>
<ul>
<li>Published: 2023</li>
<li>URL: <a href="https://www.celltherapyjournal.org/article/S2329-0501(23)00041-5/fulltext">https://www.celltherapyjournal.org/article/S2329-0501(23)00041-5/fulltext</a></li>
<li>Access: Molecular Therapy – Methods &amp; Clinical Development (open‑access article)</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite25"></a> [25] Multi‑Dimensional Due Diligence in Life Sciences Transactions</p>
<ul>
<li>Published: October 13, 2025</li>
<li>URL: <a href="https://www.gsquaredcfo.com/blog/life-sciences-due-diligence">https://www.gsquaredcfo.com/blog/life-sciences-due-diligence</a></li>
<li>Access: G‑Squared Partners due‑diligence blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite26"></a> [26] FDA Clinical Holds: When and Why</p>
<ul>
<li>Published: 2024</li>
<li>URL: <a href="https://gardner.law/insights/clinical-holds-when-and-why">https://gardner.law/insights/clinical-holds-when-and-why</a></li>
<li>Access: Gardner Law regulatory insights blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite27"></a> [27] What Every Pharma Executive Should Know About Regulatory Intelligence</p>
<ul>
<li>Published: July 23, 2025</li>
<li>URL: <a href="https://ioni.ai/post/what-every-pharma-executive-should-know-about-regulatory-intelligence">https://ioni.ai/post/what-every-pharma-executive-should-know-about-regulatory-intelligence</a></li>
<li>Access: IONI AI industry analysis</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite28"></a> [28] The 176 Guidance Documents FDA is Currently Working On</p>
<ul>
<li>Published: January 28, 2025</li>
<li>URL: <a href="https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/">https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/</a></li>
<li>Access: AgencyIQ regulatory intelligence</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite29"></a> [29] Transforming Clinical Trials to Improve Pharma ROI (Operational Delays and Efficiency Levers)</p>
<ul>
<li>Published: August 4, 2020</li>
<li>URL: <a href="https://www.iconplc.com/insights/transforming-trials">https://www.iconplc.com/insights/transforming-trials</a></li>
<li>Access: ICON PLC insights</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite30"></a> [30] Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment</p>
<ul>
<li>Published: August 24, 2018</li>
<li>URL: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment</a></li>
<li>Access: FDA guidance document</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite31"></a> [31] FDA’s Risk-Based Approach to Inspections</p>
<ul>
<li>Published: January 17, 2024</li>
<li>URL: <a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-basics/fdas-risk-based-approach-inspections">https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-basics/fdas-risk-based-approach-inspections</a></li>
<li>Access: FDA inspection basics</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite32"></a> [32] Manufacturing Control Strategy and CMC Deficiencies</p>
<ul>
<li>Published: 2025</li>
<li>URL: <a href="https://synergbiopharma.com/process-control-elements">https://synergbiopharma.com/process-control-elements</a></li>
<li>Access: Syner‑G BioPharma Group blog post</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite33"></a> [33] Clinical Data Integration Platforms and EDC Ecosystems (Medidata / Industry Overview)</p>
<ul>
<li>Published: (undated; accessed 2026-01-05)</li>
<li>URL: <a href="https://www.medidata.com/en/clinical-trial-management/">https://www.medidata.com/en/clinical-trial-management/</a></li>
<li>Access: Medidata product overview (context)</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite34"></a> [34] Digitalizing Pharma Control Strategies: A Roadmap</p>
<ul>
<li>Published: December 22, 2024</li>
<li>URL: <a href="https://www.valgenesis.com/blog/digitalizing-pharma-control-strategies-a-roadmap">https://www.valgenesis.com/blog/digitalizing-pharma-control-strategies-a-roadmap</a></li>
<li>Access: ValGenesis regulatory blog (context)</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite35"></a> [35] Financial Impact of a Day of Delay in Drug Development</p>
<ul>
<li>Published: August 2024</li>
<li>Access: Tufts Center for the Study of Drug Development (CSDD) white paper</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite36"></a> [36] CBER–CDER Pre‑IND Meeting Guidance: Generic Responses</p>
<ul>
<li>Published: December 2023</li>
<li>URL: <a href="https://seed.nih.gov/sites/default/files/2023-12/Pre-IND-Meetings-FDA.pdf">https://seed.nih.gov/sites/default/files/2023-12/Pre-IND-Meetings-FDA.pdf</a></li>
<li>Access: NIH SEED and FDA collaborative guidance (PDF)</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite37"></a> [37] Ambiguity in Pre‑IND Meeting Feedback</p>
<ul>
<li>Published: December 2023</li>
<li>URL: <a href="https://seed.nih.gov/sites/default/files/2023-12/Pre-IND-Meetings-FDA.pdf">https://seed.nih.gov/sites/default/files/2023-12/Pre-IND-Meetings-FDA.pdf</a></li>
<li>Access: NIH SEED and FDA collaborative guidance (PDF)</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite38"></a> [38] Cost of Poor Quality and Form 483 Observations</p>
<ul>
<li>Published: November 8, 2024</li>
<li>URL: <a href="https://redica.com/how-much-can-poor-quality-cost-you/">https://redica.com/how-much-can-poor-quality-cost-you/</a></li>
<li>Access: Redica Systems blog post</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite39"></a> [39] CDER Quality Management Maturity (QMM)</p>
<ul>
<li>Published: December 12, 2025</li>
<li>URL: <a href="https://www.fda.gov/drugs/biopharma/biotech-quality-resources/cder-quality-management-maturity">https://www.fda.gov/drugs/biopharma/biotech-quality-resources/cder-quality-management-maturity</a></li>
<li>Access: FDA QMM program overview</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite40"></a> [40] CBER SOPP 8410: Determining When Pre-License/Pre-Approval Inspections Are Needed and When They May Be Waived</p>
<ul>
<li>Published: January 6, 2020</li>
<li>URL: <a href="https://www.fda.gov/media/108969/download">https://www.fda.gov/media/108969/download</a></li>
<li>Access: FDA CBER SOPP (PDF)</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite41"></a> [41] Investor Valuation Drivers: Governance vs. Luck</p>
<ul>
<li>Published: October 13, 2025</li>
<li>URL: <a href="https://www.gsquaredcfo.com/blog/life-sciences-due-diligence">https://www.gsquaredcfo.com/blog/life-sciences-due-diligence</a></li>
<li>Access: G‑Squared Partners due‑diligence blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite42"></a> [42] Distinguishing Governance Quality from Luck in Investor Due Diligence</p>
<ul>
<li>Published: 2025</li>
<li>URL: <a href="https://www.gsquaredcfo.com/blog/life-sciences-due-diligence">https://www.gsquaredcfo.com/blog/life-sciences-due-diligence</a></li>
<li>Access: G‑Squared Partners due‑diligence blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite43"></a> [43] Measuring AI ROI in Drug Discovery: Key Metrics &amp; Outcomes</p>
<ul>
<li>Published: January 3 2026</li>
<li>URL: <a href="https://intuitionlabs.ai/articles/measuring-ai-roi-drug-discovery">https://intuitionlabs.ai/articles/measuring-ai-roi-drug-discovery</a></li>
<li>Access: Intuition Labs Research</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite44"></a> [44] ROI of AI in Regulatory: Case Studies from Biotech &amp; Small Pharma</p>
<ul>
<li>Published: October 12 2025</li>
<li>URL: <a href="https://numantratech.com/roi-of-ai-in-regulatory-case-studies-from-biotech-small-pharma/">https://numantratech.com/roi-of-ai-in-regulatory-case-studies-from-biotech-small-pharma/</a></li>
<li>Access: Numantra Tech Research</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite45"></a> [45] Framework to Identify Innovative Sources of Value Creation</p>
<ul>
<li>Published: May 18 2025</li>
<li>URL: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12130853/">https://pmc.ncbi.nlm.nih.gov/articles/PMC12130853/</a></li>
<li>Access: PubMed Central</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite46"></a> [46] FDA Proposes Framework to Advance Credibility of AI Models Used in Drug and Biological Products</p>
<ul>
<li>Published:May 31, 2025</li>
<li>URL: <a href="https://www.fda.gov/news-events/press-announcements/fda-proposes-framework-advance-credibility-ai-models-used-drug-and-biological-products">https://www.fda.gov/news-events/press-announcements/fda-proposes-framework-advance-credibility-ai-models-used-drug-and-biological-products</a></li>
<li>Access: FDA Official Press Announcement</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite47"></a> [47] FDA Proposes Framework to Assess AI Model Output Credibility to Support Regulatory Decision- Making</p>
<ul>
<li>Published:January 28, 2025</li>
<li>URL: <a href="https://www.cmhealthlaw.com/2025/01/fda-proposes-framework-to-assess-ai-model-output-credibility-to-support-regulatory-decision-">https://www.cmhealthlaw.com/2025/01/fda-proposes-framework-to-assess-ai-model-output-credibility-to-support-regulatory-decision-</a></li>
<li>Access: CM Health Law Analysis (Third-party Commentary)</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite48"></a> [48] Considerations for the Use of Artificial Intelligence - FDA Official Guidance</p>
<ul>
<li>Published: May 31, 2025 (Draft Guidance FDA-2024-D-4689)</li>
<li>URL: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regu">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regu</a></li>
<li>Access: FDA Official Guidance Document Library</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite49"></a> [49] Regulating the Use of AI in Drug Development: Legal Challenges and Compliance Strategies</p>
<ul>
<li>Published:August 19, 2025</li>
<li>URL: <a href="https://www.fdli.org/2025/07/regulating-the-use-of-ai-in-drug-development-legal-challenges-and-compliance-strategies/">https://www.fdli.org/2025/07/regulating-the-use-of-ai-in-drug-development-legal-challenges-and-compliance-strategies/</a></li>
<li>Access: FDA Law Institute (FDLI)</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite50"></a> [50] FDA Unveils Long-Awaited Guidance on AI Use to Support Drug and Biologic Development</p>
<ul>
<li>Published:January 20, 2025</li>
<li>URL: <a href="https://www.hoganlovells.com/en/publications/fda-unveils-longawaited-guidance-on-ai-use-to-support-drug-and-biologic-development">https://www.hoganlovells.com/en/publications/fda-unveils-longawaited-guidance-on-ai-use-to-support-drug-and-biologic-development</a></li>
<li>Access: Hogan Lovells Law Firm Analysis</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite51"></a> [51] Deciphering FDA's 7-Step Framework For AI-Driven Decision-Making</p>
<ul>
<li>Published: February 26, 2025</li>
<li>URL: <a href="https://www.bioprocessonline.com/doc/deciphering-fda-s-step-framework-for-ai-driven-decision-making-0001">https://www.bioprocessonline.com/doc/deciphering-fda-s-step-framework-for-ai-driven-decision-making-0001</a></li>
<li>Access: BioProcess Online</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite52"></a> [52] FDA's AI Guidance: 7-Step Credibility Framework Explained</p>
<ul>
<li>Published: October 19, 2018 (Updated 2025)</li>
<li>URL: <a href="https://intuitionlabs.ai/articles/fda-ai-drug-development-guidance">https://intuitionlabs.ai/articles/fda-ai-drug-development-guidance</a></li>
<li>Access: Intuition Labs</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite53"></a> [53] Regulatory Strategy Reimagined: Three Trends Accelerating Drug Development</p>
<ul>
<li>Published: November 11, 2025</li>
<li>URL: <a href="https://www.drugdiscoverytrends.com/regulatory-strategy-reimagined-three-trends-accelerating-drug-development/">https://www.drugdiscoverytrends.com/regulatory-strategy-reimagined-three-trends-accelerating-drug-development/</a></li>
<li>Access: Drug Discovery Trends</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite54"></a> [54] eCTD Resources - FDA Electronic Submission Standards</p>
<ul>
<li>Published: September 15, 2024</li>
<li>URL: <a href="https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-resources">https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-resources</a></li>
<li>Access: FDA eCTD Resources Library</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite55"></a> [55] The 176 guidance documents that FDA is currently working on affecting the life sciences industry</p>
<ul>
<li>Published: January 29, 2025</li>
<li>URL: <a href="https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/">https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/</a></li>
<li>Access: AgencyIQ blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite56"></a> [56] The 8 FDA Regulatory Trends Shaping 2026 and Beyond</p>
<ul>
<li>Published: December 8, 2025</li>
<li>URL: <a href="https://lumanity.com/perspectives/the-8-fda-regulatory-trends-shaping-2026-and-beyond/">https://lumanity.com/perspectives/the-8-fda-regulatory-trends-shaping-2026-and-beyond/</a></li>
<li>Access: Lumanity Regulatory Intelligence</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite57"></a> [57] The 176 Guidance Documents FDA is Currently Working On</p>
<ul>
<li>Published: January 28, 2025</li>
<li>URL: <a href="https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/">https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/</a></li>
<li>Access: AgencyIQ Industry Analysis</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite58"></a> [58] PDUFA VIII: Fiscal Years 2028-2032 - FDA Reauthorization</p>
<ul>
<li>Published: December 21, 2025</li>
<li>URL: <a href="https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-viii-fiscal-years-2028-2032">https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-viii-fiscal-years-2028-2032</a></li>
<li>Access: FDA Official Reauthorization Page</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite59"></a> [59] FDA's New Module 1 is a Bridge to eCTD 4</p>
<ul>
<li>Published: May 1, 2025</li>
<li>URL: <a href="https://www.certara.com/blog/fdas-new-module-1-is-a-bridge-to-ectd-4/">https://www.certara.com/blog/fdas-new-module-1-is-a-bridge-to-ectd-4/</a></li>
<li>Access: Certara Regulatory Blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite60"></a> [60] eCTD Submission Standards for eCTD v4.0 and Regional M1</p>
<ul>
<li>Published: October 19, 2025</li>
<li>URL: <a href="https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v40-and-regional-m1">https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v40-and-regional-m1</a></li>
<li>Access: FDA eCTD v4.0 Implementation Standards</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite61"></a> [61] Future of AI Regulation in Drug Development: A Comparative Analysis</p>
<ul>
<li>Published: July 10, 2025</li>
<li>URL: <a href="https://academic.oup.com/jlb/article/12/2/lsaf028/8316994">https://academic.oup.com/jlb/article/12/2/lsaf028/8316994</a></li>
<li>Access: Oxford Journal of Legal Biomedicine</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite62"></a> [62] Reimagining Drug Regulation in the Age of AI: A Framework for the AI-Enabled Ecosystem in Therapeutics</p>
<ul>
<li>Published:October 15, 2025</li>
<li>URL: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12571717/">https://pmc.ncbi.nlm.nih.gov/articles/PMC12571717/</a></li>
<li>Access: PubMed Central / Journal of Legal Biomedicine</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite63"></a> [63] The eCTD Backbone Files Specification for Module 1</p>
<ul>
<li>Published: October 31, 2012 (Updated versions ongoing)</li>
<li>URL: <a href="https://www.fda.gov/media/159382/download">https://www.fda.gov/media/159382/download</a></li>
<li>Access: FDA PDF Download</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite64"></a> [64] AI Medical Devices: FDA Draft Guidance, TPLC &amp; PCCP Guide 2025</p>
<ul>
<li>Published: October 16, 2025</li>
<li>URL: <a href="https://www.complizen.ai/post/fda-ai-medical-device-regulation-2025">https://www.complizen.ai/post/fda-ai-medical-device-regulation-2025</a></li>
<li>Access: Complizen Regulatory Intelligence</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite65"></a> [65] An Example AI Readiness in Pharma Assessment Framework</p>
<ul>
<li>Published: July 9, 2025</li>
<li>URL: <a href="https://solutionsreview.com/an-example-ai-readiness-in-pharma-assessment-framework/">https://solutionsreview.com/an-example-ai-readiness-in-pharma-assessment-framework/</a></li>
<li>Access: Solutions Review Platform</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite66"></a> [66] FDA Issues Draft Guidance Documents on Artificial Intelligence for Medical Devices</p>
<ul>
<li>Published: January 13, 2025</li>
<li>URL: <a href="https://www.sternekessler.com/news-insights/client-alerts/fda-issues-draft-guidance-documents-on-artificial-intelligence-for-med">https://www.sternekessler.com/news-insights/client-alerts/fda-issues-draft-guidance-documents-on-artificial-intelligence-for-med</a></li>
<li>Access: Sterne Kessler Law Firm Alert</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite67"></a> [67] What Does the FDA Say About the Use of AI in Clinical Trials?</p>
<ul>
<li>Published: October 21, 2025</li>
<li>URL: <a href="https://trialx.com/what-does-the-fda-say-about-the-use-of-ai-in-clinical-trials-a-summary/">https://trialx.com/what-does-the-fda-say-about-the-use-of-ai-in-clinical-trials-a-summary/</a></li>
<li>Access: TrialX Clinical Trial Platform</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite68"></a> [68] AI for Drug Development: Ensure FDA Compliance</p>
<ul>
<li>Published: June 24, 2025</li>
<li>URL: <a href="https://domino.ai/blog/ai-for-drug-development-a-roadmap-for-fda-compliance">https://domino.ai/blog/ai-for-drug-development-a-roadmap-for-fda-compliance</a></li>
<li>Access: Domino Data Lab</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite69"></a> [69] Evaluating Transparency in AI/ML Model Characteristics for FDA Submissions</p>
<ul>
<li>Published: November 16, 2025</li>
<li>URL: <a href="https://www.nature.com/articles/s41746-025-02052-9">https://www.nature.com/articles/s41746-025-02052-9</a></li>
<li>Access: Nature Digital Medicine</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite70"></a> [70] Building a Comprehensive AI Governance Framework in Life Sciences</p>
<ul>
<li>Published: November 10, 2025</li>
<li>URL: <a href="https://www.paulhastings.com/insights/client-alerts/building-a-comprehensive-ai-governance-framework-in-life-sciences">https://www.paulhastings.com/insights/client-alerts/building-a-comprehensive-ai-governance-framework-in-life-sciences</a></li>
<li>Access: Paul Hastings LLP</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite71"></a> [71] AI in Drug Development: FDA Draft Guidance Addresses Product Development</p>
<ul>
<li>Published: January   6,  2025</li>
<li>URL: <a href="https://www.raps.org/news-and-articles/news-articles/2025/1/ai-in-drug-development-fda-draft-guidance-addresse">https://www.raps.org/news-and-articles/news-articles/2025/1/ai-in-drug-development-fda-draft-guidance-addresse</a></li>
<li>Access: Regulatory Affairs Professionals Society (RAPS)</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite72"></a> [72] Artificial Intelligence in Software as a Medical Device - FDA</p>
<ul>
<li>Published: March 24, 2025</li>
<li>URL: <a href="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device">https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device</a></li>
<li>Access: FDA AI in SaMD Resource Hub</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite73"></a> [73] Episode 2: AI Regulations in Healthcare, Pharma, and Biotech</p>
<ul>
<li>Published: May 5, 2024</li>
<li>URL: <a href="https://www.modelop.com/good-decisions-series/good-decisions-ep2">https://www.modelop.com/good-decisions-series/good-decisions-ep2</a></li>
<li>Access: ModelOp Podcast Series</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite74"></a> [74] A Strategic Investor's Guide to Biopharma/biotech Portfolio Risk Assessment</p>
<ul>
<li>Published: December 10, 2025</li>
<li>URL: <a href="https://www.drugpatentwatch.com/blog/a-strategic-investors-guide-to-biopharma/biotech-portfolio-risk-assessment/">https://www.drugpatentwatch.com/blog/a-strategic-investors-guide-to-biopharma/biotech-portfolio-risk-assessment/</a></li>
<li>Access: Drug Patent Watch</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite75"></a> [75] Pharma Portfolio Management: Strategies for Success</p>
<ul>
<li>Published: December 31, 2023</li>
<li>URL: <a href="https://pipharmaintelligence.com/blog/64">https://pipharmaintelligence.com/blog/64</a></li>
<li>Access: PI Pharma Intelligence</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite76"></a> [76] Transforming Clinical Trials to Improve Pharma ROI</p>
<ul>
<li>Published: August 4, 2020</li>
<li>URL: <a href="https://www.iconplc.com/insights/transforming-trials">https://www.iconplc.com/insights/transforming-trials</a></li>
<li>Access: ICON PLC</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite77"></a> [77] Biotech Asset Valuation Methods: A Practitioner's Guide</p>
<ul>
<li>Published: 2024</li>
<li>URL: <a href="https://www.analysisgroup.com/globalassets/insights/publishing/2024-biotech-asset-valuation-methods.pdf">https://www.analysisgroup.com/globalassets/insights/publishing/2024-biotech-asset-valuation-methods.pdf</a></li>
<li>Access: Analysis Group PDF</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite78"></a> [78] Measuring the Return from Biopharma/biotech Innovation 2024</p>
<ul>
<li>Published: February 24, 2025</li>
<li>URL: <a href="https://www.deloitte.com/us/en/Industries/life-sciences-health-care/articles/measuring-return-from-biopharma/biotech-innovation.htm">https://www.deloitte.com/us/en/Industries/life-sciences-health-care/articles/measuring-return-from-biopharma/biotech-innovation.htm</a></li>
<li>Access: Deloitte Life Sciences</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite79"></a> [79] Biopharma/biotech Portfolio Management: A Complete Primer</p>
<ul>
<li>Published: May 21, 2023</li>
<li>URL: <a href="https://www.planview.com/resources/articles/biopharma/biotech-portfolio-management-a-complete-primer/">https://www.planview.com/resources/articles/biopharma/biotech-portfolio-management-a-complete-primer/</a></li>
<li>Access: Planview Resources</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite80"></a> [80] Transition Acceleration Framework: A New Approach for Private Capital</p>
<ul>
<li>Published: September 10, 2025</li>
<li>URL: <a href="https://intelligence.generatecapital.com/transition-acceleration-framework/">https://intelligence.generatecapital.com/transition-acceleration-framework/</a></li>
<li>Access: Generate Capital Research</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite81"></a> [81] Microsoft Copilot Adoption: 12 vs 24-Week Rollouts for Pharma</p>
<ul>
<li>Published: December 30, 2025</li>
<li>URL: <a href="https://www.adoptify.ai/blogs/microsoft-copilot-adoption-12-vs-24-week-rollouts-for-pharma/">https://www.adoptify.ai/blogs/microsoft-copilot-adoption-12-vs-24-week-rollouts-for-pharma/</a></li>
<li>Access: Adoptify AI Implementation</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite82"></a> [82] Regulatory Governance and the Evolution of Lean Regulators</p>
<ul>
<li>Published: October 18, 2025</li>
<li>URL: <a href="https://journalwjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2025-0919.pdf">https://journalwjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2025-0919.pdf</a></li>
<li>Access: World Journal of Biological Pharmacy &amp; Health Sciences</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite83"></a> [83] Driving Strategic Excellence in Biopharma/biotech: A Manager's Guide</p>
<ul>
<li>Published: March 16, 2025</li>
<li>URL: <a href="https://kanboapp.com/en/teams/management-teams/driving-strategic-excellence-in-biopharma/biotech-a-managers-guide-to-harnessing-fr">https://kanboapp.com/en/teams/management-teams/driving-strategic-excellence-in-biopharma/biotech-a-managers-guide-to-harnessing-fr</a></li>
<li>Access: Kanbo App Blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite84"></a> [84] Governance Models for RA-QA Alignment in FDA-Regulated Companies</p>
<ul>
<li>Published: December 18, 2025</li>
<li>URL: <a href="https://www.pharmaregulatory.in/governance-models-for-ra-qa-alignment-in-fda-regulated-companies/">https://www.pharmaregulatory.in/governance-models-for-ra-qa-alignment-in-fda-regulated-companies/</a></li>
<li>Access: Pharma Regulatory India</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite85"></a> [85] Biopharma/biotech Competitive Intelligence: 2026 Guide</p>
<ul>
<li>Published: December 31, 2025</li>
<li>URL: <a href="https://www.biopharmavantage.com/competitive-intelligence">https://www.biopharmavantage.com/competitive-intelligence</a></li>
<li>Access: BioPharma Vantage</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite86"></a> [86] The Role of Implementation Science in Achieving Scale and Adoption</p>
<ul>
<li>Published: July 22, 2025</li>
<li>URL: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12395526/">https://pmc.ncbi.nlm.nih.gov/articles/PMC12395526/</a></li>
<li>Access: PubMed Central</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite87"></a> [87] FDA Regulatory Strategy, Federal Policy Development and Advocacy</p>
<ul>
<li>Published: September 16, 2025</li>
<li>URL: <a href="https://leavittpartners.com/fda-regulatory-strategy-federal-policy-development-and-advocacy-and-alliance-building/">https://leavittpartners.com/fda-regulatory-strategy-federal-policy-development-and-advocacy-and-alliance-building/</a></li>
<li>Access: Leavitt Partners</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite88"></a> [88] Top Three Change Management Tips for Rolling Out AI Insights</p>
<ul>
<li>Published: May 19, 2025</li>
<li>URL: <a href="https://marketlogicsoftware.com/blog/top-three-change-management-tips-for-rolling-out-ai-insights/">https://marketlogicsoftware.com/blog/top-three-change-management-tips-for-rolling-out-ai-insights/</a></li>
<li>Access: Market Logic Software</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite89"></a> [89] Navigating FDA Regulatory Changes: Policy Shifts &amp; Future Oversight</p>
<ul>
<li>Published: June 22, 2025</li>
<li>URL: <a href="https://www.clinicalleader.com/doc/navigating-fda-regulatory-changes-policy-shifts-deregulation-restructuring-and-future-oversig">https://www.clinicalleader.com/doc/navigating-fda-regulatory-changes-policy-shifts-deregulation-restructuring-and-future-oversig</a></li>
<li>Access: Clinical Leader Magazine</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite90"></a> [90] Change Management: The Hidden Hurdle of AI Adoption</p>
<ul>
<li>Published: September 15, 2024</li>
<li>URL: <a href="https://www.artosai.com/blog/change-management-the-hidden-hurdle-of-ai-adoption">https://www.artosai.com/blog/change-management-the-hidden-hurdle-of-ai-adoption</a></li>
<li>Access: Artos AI Blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite91"></a> [91] IT Operating Plan - FDA</p>
<ul>
<li>Published: January 16, 2025</li>
<li>URL: <a href="https://www.fda.gov/media/185225/download">https://www.fda.gov/media/185225/download</a></li>
<li>Access: FDA PDF Download</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite92"></a> [92] What Every Pharma Executive Should Know About Regulatory Intelligence</p>
<ul>
<li>Published: July 23, 2025</li>
<li>URL: <a href="https://ioni.ai/post/what-every-pharma-executive-should-know-about-regulatory-intelligence">https://ioni.ai/post/what-every-pharma-executive-should-know-about-regulatory-intelligence</a></li>
<li>Access: IONI AI</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite93"></a> [93] Medicare Drug Price Negotiation Program: Final Guidance</p>
<ul>
<li>Published: October 1, 2024</li>
<li>URL: <a href="https://www.cms.gov/files/document/medicare-drug-price-negotiation-final-guidance-ipay-2027-and-manufacturer-effectuation-mfp-20">https://www.cms.gov/files/document/medicare-drug-price-negotiation-final-guidance-ipay-2027-and-manufacturer-effectuation-mfp-20</a></li>
<li>Access: CMS PDF Download</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite94"></a> [94] A Strategic Investor’s Guide to Biopharma/biotech Portfolio Risk Assessment</p>
<ul>
<li>Published: December 11, 2025</li>
<li>URL: <a href="https://www.drugpatentwatch.com/blog/a-strategic-investors-guide-to-biopharma/biotech-portfolio-risk-assessment/">https://www.drugpatentwatch.com/blog/a-strategic-investors-guide-to-biopharma/biotech-portfolio-risk-assessment/</a></li>
<li>Access: DrugPatentWatch blog</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite95"></a> [95] Governance Models for RA–QA Alignment in FDA‑Regulated Companies</p>
<ul>
<li>Published: December 19, 2025</li>
<li>URL: <a href="https://www.pharmaregulatory.in/governance-models-for-ra-qa-alignment-in-fda-regulated-companies/">https://www.pharmaregulatory.in/governance-models-for-ra-qa-alignment-in-fda-regulated-companies/</a></li>
<li>Access: PharmaRegulatory.in – India's Regulatory Knowledge Hub</li>
<li>Status: ✓ Active</li>
</ul>
<p><a id="cite96"></a> [96] FDA Oversight: Understanding the Regulation of Health AI Tools</p>
<ul>
<li>Published: November 10, 2025</li>
<li>URL: <a href="https://bipartisanpolicy.org/issue-brief/fda-oversight-understanding-the-regulation-of-health-ai-tools/">https://bipartisanpolicy.org/issue-brief/fda-oversight-understanding-the-regulation-of-health-ai-tools/</a></li>
<li>Access: Bipartisan Policy Center issue brief</li>
<li>Status: ✓ Active</li>
</ul>
<hr />
              
            </div>
          </div><footer>
    <div class="rst-footer-buttons" role="navigation" aria-label="Footer Navigation">
        <a href="../acknowledgements/" class="btn btn-neutral float-left" title="Acknowledgements"><span class="icon icon-circle-arrow-left"></span> Previous</a>
        <a href="../appendix-a/" class="btn btn-neutral float-right" title="Appendix A">Next <span class="icon icon-circle-arrow-right"></span></a>
    </div>

  <hr/>

  <div role="contentinfo">
    <!-- Copyright etc -->
      <p>Copyright &copy; 2026 Mark Julius Banasihan<br></p>
  </div>

  Built with <a href="https://www.mkdocs.org/">MkDocs</a> using a <a href="https://github.com/readthedocs/sphinx_rtd_theme">theme</a> provided by <a href="https://readthedocs.org">Read the Docs</a>.
</footer>
          
        </div>
      </div>

    </section>

  </div>

  <div class="rst-versions" role="note" aria-label="Versions">
  <span class="rst-current-version" data-toggle="rst-current-version">
    
    
      <span><a href="../acknowledgements/" style="color: #fcfcfc">&laquo; Previous</a></span>
    
    
      <span><a href="../appendix-a/" style="color: #fcfcfc">Next &raquo;</a></span>
    
  </span>
</div>
    <script src="../../js/jquery-3.6.0.min.js"></script>
    <script>var base_url = "../..";</script>
    <script src="../../js/theme_extra.js"></script>
    <script src="../../js/theme.js"></script>
      <script src="../../search/main.js"></script>
    <script>
        jQuery(function () {
            SphinxRtdTheme.Navigation.enable(true);
        });
    </script>

</body>
</html>
